NYSE:GSK - GlaxoSmithKline Stock Price, News, & Analysis

$40.12
-0.01 (-0.02 %)
(As of 06/16/2019 04:00 PM ET)
Today's Range
$39.92
Now: $40.12
$40.15
50-Day Range
$38.64
MA: $39.75
$41.13
52-Week Range
$36.41
Now: $40.12
$42.32
Volume1.84 million shs
Average Volume2.11 million shs
Market Capitalization$99.52 billion
P/E Ratio12.70
Dividend Yield4.86%
Beta0.74
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CUSIPN/A
Phone44-20-8047-5000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$41.14 billion
Cash Flow$4.1575 per share
Book Value$1.98 per share

Profitability

Net Income$4.84 billion

Miscellaneous

Employees95,490
Outstanding Shares2,480,600,000
Market Cap$99.52 billion
Next Earnings Date7/24/2019 (Estimated)
OptionableOptionable

Receive GSK News and Ratings via Email

Sign-up to receive the latest news and ratings for GSK and its competitors with MarketBeat's FREE daily newsletter.

GlaxoSmithKline (NYSE:GSK) Frequently Asked Questions

What is GlaxoSmithKline's stock symbol?

GlaxoSmithKline trades on the New York Stock Exchange (NYSE) under the ticker symbol "GSK."

How often does GlaxoSmithKline pay dividends? What is the dividend yield for GlaxoSmithKline?

GlaxoSmithKline announced a quarterly dividend on Friday, May 3rd. Shareholders of record on Friday, May 17th will be paid a dividend of $0.4953 per share on Thursday, July 11th. This represents a $1.98 dividend on an annualized basis and a yield of 4.94%. The ex-dividend date is Thursday, May 16th. View GlaxoSmithKline's Dividend History.

How were GlaxoSmithKline's earnings last quarter?

GlaxoSmithKline plc (NYSE:GSK) posted its quarterly earnings data on Wednesday, May, 1st. The pharmaceutical company reported $0.79 earnings per share for the quarter, beating analysts' consensus estimates of $0.66 by $0.13. The pharmaceutical company had revenue of $9.98 billion for the quarter, compared to the consensus estimate of $9.86 billion. GlaxoSmithKline had a net margin of 12.27% and a return on equity of 171.27%. View GlaxoSmithKline's Earnings History.

When is GlaxoSmithKline's next earnings date?

GlaxoSmithKline is scheduled to release their next quarterly earnings announcement on Wednesday, July 24th 2019. View Earnings Estimates for GlaxoSmithKline.

What guidance has GlaxoSmithKline issued on next quarter's earnings?

GlaxoSmithKline updated its FY 2019 earnings guidance on Wednesday, May, 1st. The company provided earnings per share (EPS) guidance of $1.38-1.44 for the period, compared to the Thomson Reuters consensus EPS estimate of $2.91.

What price target have analysts set for GSK?

18 brokerages have issued 1-year target prices for GlaxoSmithKline's stock. Their forecasts range from $36.95 to $47.00. On average, they expect GlaxoSmithKline's stock price to reach $41.9917 in the next twelve months. This suggests a possible upside of 4.7% from the stock's current price. View Analyst Price Targets for GlaxoSmithKline.

What is the consensus analysts' recommendation for GlaxoSmithKline?

18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GlaxoSmithKline in the last year. There are currently 1 sell rating, 14 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for GlaxoSmithKline.

Has GlaxoSmithKline been receiving favorable news coverage?

News articles about GSK stock have trended somewhat positive recently, InfoTrie reports. InfoTrie scores the sentiment of media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. GlaxoSmithKline earned a news impact score of 1.7 on InfoTrie's scale. They also assigned headlines about the pharmaceutical company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the company's share price in the near term. View News Stories for GlaxoSmithKline.

Who are some of GlaxoSmithKline's key competitors?

What other stocks do shareholders of GlaxoSmithKline own?

Based on aggregate information from My MarketBeat watchlists, some companies that other GlaxoSmithKline investors own include AT&T (T), Pfizer (PFE), Verizon Communications (VZ), Cisco Systems (CSCO), Bank of America (BAC), Johnson & Johnson (JNJ), General Electric (GE), Intel (INTC), Exxon Mobil (xom) and Gilead Sciences (GILD).

Who are GlaxoSmithKline's key executives?

GlaxoSmithKline's management team includes the folowing people:
  • Ms. Emma N. Walmsley, CEO & Director (Age 49)
  • Mr. Simon P. Dingemans, CFO & Exec. Director (Age 55)
  • Dr. Hal V. Barron, Chief Scientific Officer, Pres of R&D and Director (Age 56)
  • Mr. Jack Bailey, Pres of US Pharmaceuticals
  • Ms. Karenann K. Terrell, Chief Digital & Technology Officer (Age 57)

Who are GlaxoSmithKline's major shareholders?

GlaxoSmithKline's stock is owned by a number of of retail and institutional investors. Top institutional investors include FMR LLC (0.70%), Federated Investors Inc. PA (0.16%), Equity Investment Corp (0.11%), Parametric Portfolio Associates LLC (0.11%), Northern Trust Corp (0.11%) and Brandes Investment Partners LP (0.08%). View Institutional Ownership Trends for GlaxoSmithKline.

Which institutional investors are selling GlaxoSmithKline stock?

GSK stock was sold by a variety of institutional investors in the last quarter, including Chartwell Investment Partners LLC, Klingenstein Fields & Co. LLC, Northern Trust Corp, FMR LLC, Confluence Investment Management LLC, Boston Partners, Kornitzer Capital Management Inc. KS and SG Americas Securities LLC. View Insider Buying and Selling for GlaxoSmithKline.

Which institutional investors are buying GlaxoSmithKline stock?

GSK stock was bought by a variety of institutional investors in the last quarter, including Foundry Partners LLC, CIBC Asset Management Inc, Trexquant Investment LP, Cohen Klingenstein LLC, Mercer Global Advisors Inc. ADV, Parametric Portfolio Associates LLC, Equity Investment Corp and Mercer Global Advisors Inc. ADV. View Insider Buying and Selling for GlaxoSmithKline.

How do I buy shares of GlaxoSmithKline?

Shares of GSK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is GlaxoSmithKline's stock price today?

One share of GSK stock can currently be purchased for approximately $40.12.

How big of a company is GlaxoSmithKline?

GlaxoSmithKline has a market capitalization of $99.52 billion and generates $41.14 billion in revenue each year. The pharmaceutical company earns $4.84 billion in net income (profit) each year or $3.16 on an earnings per share basis. GlaxoSmithKline employs 95,490 workers across the globe.View Additional Information About GlaxoSmithKline.

What is GlaxoSmithKline's official website?

The official website for GlaxoSmithKline is http://www.gsk.com/.

How can I contact GlaxoSmithKline?

GlaxoSmithKline's mailing address is 980 GREAT WEST ROAD, BRENTFORD MIDDLESEX X0, TW8 9GS. The pharmaceutical company can be reached via phone at 44-20-8047-5000 or via email at [email protected]


MarketBeat Community Rating for GlaxoSmithKline (NYSE GSK)

Community Ranking:  1.9 out of 5 (star)
Outperform Votes:  574 (Thanks for Voting!)
Underperform Votes:  935 (Thanks for Voting!)
Total Votes:  1,509
MarketBeat's community ratings are surveys of what our community members think about GlaxoSmithKline and other stocks. Vote "Outperform" if you believe GSK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GSK will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/16/2019 by MarketBeat.com Staff

Featured Article: Dividend Achievers

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel